Exelixis (EXEL) stock had a bullish inflow of $1.22 million worth of trades on uptick and an outflow of $0.82 million in downticks on Wednesday. The total uptick to downtick ratio stood at 1.49. The net money flow into the stock was $0.4 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $0.61 million. $0.61 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. However, Exelixis (EXEL) stock traded down $0.13 , and reached $15.35, a drop of -0.82% over the previous day. On a weekly basis, the stock is 3.11%, over the previous weeks close.
Exelixis, Inc. has dropped 9.43% in the last five trading days, however, the shares have posted positive gains of 21.58% in the last 4 weeks. Exelixis, Inc. is up 71.15% in the last 3-month period. Year-to-Date the stock performance stands at 136.7%.
Exelixis (EXEL) : 4 brokerage houses believe that Exelixis (EXEL) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Exelixis (EXEL). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 5 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.4.
Exelixis (NASDAQ:EXEL): stock was range-bound between the intraday low of $12.07 and the intraday high of $15.58 after having opened at $15.57 on Wednesdays session. The stock finally closed in the red at $15.57, a loss of -13.76%. The stock remained in the red for the whole trading day. The total traded volume was 28,072,608 shares. The stock failed to cross $15.58 in Wednesdays trading. The stocks closing price on Thursday was $15.48.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).